GlassScriptPhysician profile
Alex Baher
NPI 1871814335
$17,852.53
in general payments reported to CMS, 2019-2025
33 companies · $2,959 in 2025
The $2,959 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,883 · 2020: $3,559 · 2021: $1,668 · 2022: $1,519 · 2023: $1,126 · 2024: $1,140 · 2025: $2,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,563 · Travel and Lodging: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,563.18 |
| Travel and Lodging | $661.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,452.93 | 2019-2025 | Aveir, Amplatzer Amulet, Perclose Prostyle |
| Boston Scientific Corporation | $3,337.86 | 2019-2025 | Watchman Flx, Watchman, Farapulse |
| Medtronic Vascular, INC. | $2,035.74 | 2019-2020 | |
| Biosense Webster, INC. | $912.86 | 2019-2025 | Carto 3, Qdot Micro Catheter |
| Biotronik INC. | $689.51 | 2020-2023 | Biomonitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $389.52 | 2020-2025 | Lifevest |
| Cook Incorporated | $296.39 | 2022 | |
| Medtronic, INC. | $266.79 | 2023-2024 | Na, Micra, Ffrangio |
| Philips North America LLC | $172.71 | 2023-2025 | Lm Undivided |
| E.R. Squibb & Sons, L.L.C. | $168.24 | 2024-2025 | Eliquis, Camzyos |
| Cook Medical LLC | $164.35 | 2019 | |
| Pfizer INC. | $119.86 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $92.63 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $88.97 | 2023-2025 | Onpattro |
| Amgen INC. | $73.18 | 2024-2025 | Repatha, Repatha |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.25 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $59.26 | 2024-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $56.55 | 2025 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $53.16 | 2024 | Uptravi, Opsumit |
| Elutia, INC. | $46.17 | 2023-2024 | Ecm Patch,Pouch |
| Kestra Medical Technology Services, INC. | $43.98 | 2025 | Assure Wcd |
| Abiomed | $35.70 | 2022-2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $34.49 | 2024-2025 | |
| Atricure, INC. | $26.84 | 2024 | |
| Penumbra, INC. | $23.78 | 2025 | Penumbra System |
| Lilly USA, LLC | $23.44 | 2025 | Zepbound |
| Impulse Dynamics (USA) INC. | $23.18 | 2024 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $20.87 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $18.14 | 2023 | Xarelto |
| Cardiva Medical, INC. | $17.26 | 2024 | Optowire |
| Baxter Healthcare | $16.99 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Scpharmaceuticals INC. | $14.06 | 2025 | |
| Bridgebio Pharma, INC. | $13.87 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Baher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.